CHM.AX Chimeric Therapeutics (ASX) A$0.002 on 26 Feb 2026: earnings set catalysts
CHM.AX stock closed at A$0.002 on the ASX after Chimeric Therapeutics Limited released earnings details on 26 Feb 2026. We see a clinical-stage biotech still burning cash but holding meaningful trial assets. Today’s report confirms EPS of -0.01 and a market capitalisation near A$8.84m, keeping attention on upcoming trial readouts and funding needs. This earnings spotlight outlines key metrics, risks, and realistic price targets for investors.
CHM.AX stock: earnings snapshot and headline figures
Chimeric Therapeutics (CHM.AX) reported the earnings announcement dated 26 Feb 2026. The company shows EPS -0.01 and a trailing PE of -0.20. Revenue per share is A$0.00538 and net income per share is -A$0.00392. We link the results directly to today’s unchanged price of A$0.002 and note limited near-term operational revenue. Investors should treat this as a clinical-stage update rather than a profitability signal.
CHM.AX stock: price action, volume and liquidity
CHM.AX closed at A$0.002 with volume 59,797,051 shares versus average volume 5,119,507. Year high and low are A$0.009 and A$0.002 respectively. Fifty-day average price is A$0.00245 and 200-day average price is A$0.00338. High intraday volume and wide share count create volatility. Shares outstanding stand at 4,418,707,619, so dilution or capital raises will significantly affect per-share metrics.
CHM.AX stock: fundamentals, cash and valuation metrics
Key ratios show a mixed picture. Market cap is A$8.84m, price-to-sales is 0.97, and price-to-book is 1.72. Cash per share is A$0.00340 while book value per share is A$0.00117. Current ratio is 0.72, signaling limited short-term liquidity. Research spend is high relative to revenue, with R&D-to-revenue at 1.01x. These metrics highlight early-stage funding risk alongside a low absolute valuation.
Meyka AI rating and CHM.AX stock technicals
Meyka AI rates CHM.AX with a score out of 100: 65.87 | Grade B | HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technicals show RSI 44.15 and ADX 60.15, indicating trend strength but neutral momentum. The 50/200 averages imply the stock trades below longer-term average prices, consistent with a recovery-required thesis.
CHM.AX stock: clinical pipeline, sector context and catalysts
Chimeric Therapeutics is a clinical-stage biotech developing NK and CAR platforms, including CHM 0201 and CHM 1101 in phase I trials. The healthcare sector in Australia is down YTD -7.34%, reducing peer valuation multiples. Upcoming clinical readouts, partnership updates, or licensing deals are the primary catalysts. Positive trial news could re-rate the stock, while delays or negative safety signals would depress valuation further.
CHM.AX stock: risks, upside scenarios and price targets
Principal risks are cash runway, dilution, trial execution, and low liquidity. We frame price targets as scenario-based. A conservative short-term target is A$0.003, a base-case 12-month target is A$0.006, and a high-case on positive readouts is A$0.010. These reflect the company’s tiny market cap and binary clinical catalysts. Any target assumes successful trial milestones or new funding without excessive dilution.
Final Thoughts
CHM.AX stock trades at A$0.002 after the 26 Feb 2026 earnings update. The report confirms negative earnings but preserves the clinical assets that can drive value. Our view separates operational weakness from pipeline potential. Meyka AI’s forecast model projects A$0.006 at 12 months, implying +200.00% from the current price of A$0.002. Forecasts are model-based projections and not guarantees. Given the small market cap A$8.84m, large share count 4,418,707,619, and modest cash per share, investors should expect high volatility and potential dilution. We rate CHM.AX as a speculative, research-driven holding that benefits from targeted risk management. For real-time updates, see the Meyka stock page and monitor upcoming trial milestones closely.
FAQs
What is the current CHM.AX stock price and market cap?
CHM.AX stock closed at A$0.002 on 26 Feb 2026. Market capitalisation is approximately A$8.84m with 4,418,707,619 shares outstanding. Volume on the day was 59,797,051 shares.
Did CHM.AX report earnings today and what mattered?
Yes. The earnings announcement dated 26 Feb 2026 showed EPS -0.01 and no operational profitability. Key items were R&D spend levels and cash per share, which frame runway and funding needs ahead of trial readouts.
What is Meyka AI’s view and forecast for CHM.AX stock?
Meyka AI rates CHM.AX with a score out of 100: 65.87 | Grade B | HOLD. Meyka AI’s forecast model projects A$0.006 in 12 months from the current A$0.002. Forecasts are model-based projections and not guarantees.
What are the main catalysts and risks for CHM.AX stock?
Primary catalysts are clinical readouts, partnerships, or licensing deals. Main risks include trial failure, cash runway constraints, dilution, and low liquidity given the small market cap.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.